RAPP
USDRapport Therapeutics Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$26.440
고가
$26.440
저가
$24.600
거래량
0.24M
기업 기본 정보
시가총액
1.2B
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.80M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Truist Securities Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $44
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics with a Buy rating and announces Price Target of $44.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Pricing of Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Proposed Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics with a Buy and raises the price target from $31 to $34.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for
